Abstract Number: 1363 • 2019 ACR/ARP Annual Meeting
Longitudinal Work Transitions in Early Inflammatory Arthritis Patients: Are There Targets for Intervention to Improve Employment?
Background/Purpose: Historically, increasing proportions of patients with rheumatoid arthritis stop working on long-term follow-up, often due to arthritis. The trajectory of work transitions in early…Abstract Number: 1364 • 2019 ACR/ARP Annual Meeting
Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients
Background/Purpose: The goal for treatment of RA is to obtain low disease activity for better outcomes. In order to achieve low disease activity, it is…Abstract Number: 1365 • 2019 ACR/ARP Annual Meeting
Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States
Background/Purpose: Use of PROs to assess health-related quality of life in clinical practice, research studies, and clinical trials in Rheumatoid Arthritis (RA) remains an ongoing…Abstract Number: 1366 • 2019 ACR/ARP Annual Meeting
Self-joint Counts by People with Rheumatoid Arthritis: Does a Video Increase Accuracy and Does It Matter?
Background/Purpose: As a tool for self-monitoring and reporting RA disease activity, a smartphone app was developed to enable people with rheumatoid arthritis (RA) to record…Abstract Number: 1367 • 2019 ACR/ARP Annual Meeting
An Engineered Glove for the Computerised Quantification of Hand Disability in Rheumatoid Arthritis
Background/Purpose: Background Rheumatoid arthritis (RA) is a long-term, progressive, and disabling autoimmune disease. The disease activity can be quantified by the Disease Activity Score 28-joint count…Abstract Number: 1368 • 2019 ACR/ARP Annual Meeting
One Size Fits All : Replacing ESR by γGT in DAS28 Calculation Permits a Dual Evaluation of Joint Activity Together with Cardiovascular Risk
Background/Purpose: Patients with rheumatoid arthritis (RA) experience premature mortality that is largely due to cardiovascular disease (CVD). Ample evidence suggests that elevated γGT activity is…Abstract Number: 1369 • 2019 ACR/ARP Annual Meeting
Angiogenic Factors for Assessing Rheumatoid Arthritis in the Era of Sonographic Diagnosis and Biologic Therapy
Background/Purpose: Previously, we demonstrated the direct pro-inflammatory role of the vascular endothelial growth factor (VEGF) and the placenta growth factor (PlGF), and angiogenic factors in…Abstract Number: 1370 • 2019 ACR/ARP Annual Meeting
Not All Joints Are Equal: Challenge DAS28 System and Identify Factors Leading to a Mismatch Between T2T and HAQ Among RA Patients Through Data Mining from Smart System of Disease Management (SSDM)
Background/Purpose: Treat to target (T2T), achieving a DAS28 score lower than 3.2, is the strategy recommended by ACR and EULAR. Health assessment questionnaire (HAQ) is…Abstract Number: 1371 • 2019 ACR/ARP Annual Meeting
Create an Algorithm of Outcome Forecasting and Decision Making for RA Treatment: Data Mining and Machine Learning via the Smart System of Disease Management (SSDM)
Background/Purpose: Daily health care deals with a wide spectrum of RA patients from statuses of remission (R) to disease activities at low (L), moderate (M)…Abstract Number: 1372 • 2019 ACR/ARP Annual Meeting
Adherence to Treatment with Intravenous Biological Agents in Patients with Rheumatoid Arthritis
Background/Purpose: The adherence to the therapeutic regimen in patients with Rheumatoid Arthritis (RA) varies between 30 and 80%. Classically, it is mentioned that the adherence…Abstract Number: 1373 • 2019 ACR/ARP Annual Meeting
Performance of CQR5 vs CQR19 in the Evaluation of Adherence to Tofacitinib in Daily Clinical Practice
Background/Purpose: To evaluate the adherence to treatment with Tofacitinib in patients with Rheumatoid Arthritis (RA) using both versions of the self-questionnaire Compliance Questionnaire Rheumatology: CQR19…Abstract Number: 1374 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Background/Purpose: Infections are common safety events monitored in RA patients.1 ACR guidelines limit the use of live vaccines in patients who are on biologic (b)DMARDs…Abstract Number: 1375 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
Background/Purpose: In patients with active rheumatoid arthritis (RA), 12-week treatment with upadacitinib (UPA) while on background MTX therapy resulted in significant and clinically meaningful improvements…Abstract Number: 1376 • 2019 ACR/ARP Annual Meeting
Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
Background/Purpose: Treatment with upadacitinib (UPA) monotherapy, a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week…Abstract Number: 1377 • 2019 ACR/ARP Annual Meeting
MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib +/- background MTX has been shown to be an effective treatment…
ACR Meeting Abstracts